Carisma Therapeutics (NASDAQ:CARM) Price Target Cut to $12.00 by Analysts at D. Boral Capital

Carisma Therapeutics (NASDAQ:CARM) had its price objective decreased by analysts at D. Boral Capital from $24.00 to $12.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

CARM has been the subject of several other research reports. HC Wainwright dropped their target price on Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, November 25th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th.

Carisma Therapeutics Trading Down 0.4 %

CARM traded down $0.00 on Monday, hitting $0.80. The company had a trading volume of 143,779 shares, compared to its average volume of 328,605. The company has a market cap of $33.22 million, a PE ratio of -0.51 and a beta of 1.45. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The business’s fifty day simple moving average is $0.94 and its 200 day simple moving average is $1.06. Carisma Therapeutics has a 12-month low of $0.79 and a 12-month high of $3.16.

Carisma Therapeutics (NASDAQ:CARM) last announced its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). The business had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. Equities research analysts expect that Carisma Therapeutics will post -1.32 EPS for the current year.

Institutional Trading of Carisma Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Carisma Therapeutics in the second quarter valued at about $40,000. Wexford Capital LP raised its position in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the last quarter. Barclays PLC boosted its stake in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Carisma Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock worth $3,587,000 after purchasing an additional 11,200 shares during the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.